Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
PIPE-791 Dose A
PIPE-791 Dose B
+1 more
Locations
2
Canada
Dynamic Drug Advancement Ltd.
Ajax, Ontario, Canada
Dr. Anil Dhar Medicine Professional Corporation
Windsor, Ontario, Canada
Start Date
January 8, 2026
Primary Completion Date
May 1, 2028
Completion Date
June 1, 2028
Last Updated
February 4, 2026
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT03500731
Lead Sponsor
Contineum Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions